538 related articles for article (PubMed ID: 14985429)
1. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway.
Lee HJ; Khoshaghideh F; Patel S; Lee SJ
J Neurosci; 2004 Feb; 24(8):1888-96. PubMed ID: 14985429
[TBL] [Abstract][Full Text] [Related]
2. Rotenone induces aggregation of gamma-tubulin protein and subsequent disorganization of the centrosome: relevance to formation of inclusion bodies and neurodegeneration.
Diaz-Corrales FJ; Asanuma M; Miyazaki I; Miyoshi K; Ogawa N
Neuroscience; 2005; 133(1):117-35. PubMed ID: 15893636
[TBL] [Abstract][Full Text] [Related]
3. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.
Sherer TB; Betarbet R; Stout AK; Lund S; Baptista M; Panov AV; Cookson MR; Greenamyre JT
J Neurosci; 2002 Aug; 22(16):7006-15. PubMed ID: 12177198
[TBL] [Abstract][Full Text] [Related]
4. Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons.
McLean PJ; Kawamata H; Hyman BT
Neuroscience; 2001; 104(3):901-12. PubMed ID: 11440819
[TBL] [Abstract][Full Text] [Related]
5. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.
Ardley HC; Scott GB; Rose SA; Tan NG; Robinson PA
J Neurochem; 2004 Jul; 90(2):379-91. PubMed ID: 15228595
[TBL] [Abstract][Full Text] [Related]
6. Synphilin-1 degradation by the ubiquitin-proteasome pathway and effects on cell survival.
Lee G; Junn E; Tanaka M; Kim YM; Mouradian MM
J Neurochem; 2002 Oct; 83(2):346-52. PubMed ID: 12423244
[TBL] [Abstract][Full Text] [Related]
7. Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease.
Meredith GE; Totterdell S; Petroske E; Santa Cruz K; Callison RC; Lau YS
Brain Res; 2002 Nov; 956(1):156-65. PubMed ID: 12426058
[TBL] [Abstract][Full Text] [Related]
8. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
9. Induction of alpha-synuclein aggregation by intracellular nitrative insult.
Paxinou E; Chen Q; Weisse M; Giasson BI; Norris EH; Rueter SM; Trojanowski JQ; Lee VM; Ischiropoulos H
J Neurosci; 2001 Oct; 21(20):8053-61. PubMed ID: 11588178
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
11. Challenges and complexities of alpha-synuclein toxicity: new postulates in unfolding the mystery associated with Parkinson's disease.
Hegde ML; Jagannatha Rao KS
Arch Biochem Biophys; 2003 Oct; 418(2):169-78. PubMed ID: 14522588
[TBL] [Abstract][Full Text] [Related]
12. Neuropathological spectrum of synucleinopathies.
Jellinger KA
Mov Disord; 2003 Sep; 18 Suppl 6():S2-12. PubMed ID: 14502650
[TBL] [Abstract][Full Text] [Related]
13. Degradative organelles containing mislocalized alpha-and beta-synuclein proliferate in presenilin-1 null neurons.
Wilson CA; Murphy DD; Giasson BI; Zhang B; Trojanowski JQ; Lee VM
J Cell Biol; 2004 May; 165(3):335-46. PubMed ID: 15123735
[TBL] [Abstract][Full Text] [Related]
14. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors.
Lee HJ; Shin SY; Choi C; Lee YH; Lee SJ
J Biol Chem; 2002 Feb; 277(7):5411-7. PubMed ID: 11724769
[TBL] [Abstract][Full Text] [Related]
15. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death.
Stefanis L; Larsen KE; Rideout HJ; Sulzer D; Greene LA
J Neurosci; 2001 Dec; 21(24):9549-60. PubMed ID: 11739566
[TBL] [Abstract][Full Text] [Related]
16. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity.
Ostrerova-Golts N; Petrucelli L; Hardy J; Lee JM; Farer M; Wolozin B
J Neurosci; 2000 Aug; 20(16):6048-54. PubMed ID: 10934254
[TBL] [Abstract][Full Text] [Related]
17. A single amino acid substitution in a proteasome subunit triggers aggregation of ubiquitinated proteins in stressed neuronal cells.
Li Z; Arnaud L; Rockwell P; Figueiredo-Pereira ME
J Neurochem; 2004 Jul; 90(1):19-28. PubMed ID: 15198663
[TBL] [Abstract][Full Text] [Related]
18. Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity.
Usenovic M; Tresse E; Mazzulli JR; Taylor JP; Krainc D
J Neurosci; 2012 Mar; 32(12):4240-6. PubMed ID: 22442086
[TBL] [Abstract][Full Text] [Related]
19. Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein.
Lauwers E; Debyser Z; Van Dorpe J; De Strooper B; Nuttin B; Baekelandt V
Brain Pathol; 2003 Jul; 13(3):364-72. PubMed ID: 12946025
[TBL] [Abstract][Full Text] [Related]
20. Alpha-synuclein: its biological function and role in neurodegenerative diseases.
Kaplan B; Ratner V; Haas E
J Mol Neurosci; 2003 Apr; 20(2):83-92. PubMed ID: 12794302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
